Search Results - "Matulonis, U.A" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

by Liu, J.F., Barry, W.T., Birrer, M., Lee, J.-M., Buckanovich, R.J., Fleming, G.F., Rimel, B.J., Buss, M.K., Nattam, S.R., Hurteau, J., Luo, W., Curtis, J., Whalen, C., Kohn, E.C., Ivy, S.P., Matulonis, U.A.
Published in Annals of oncology (01.04.2019)

Get full text

Journal Article

Safety and dose modification for patients receiving niraparib

Safety and dose modification for patients receiving niraparib

by Berek, J.S., Matulonis, U.A., Peen, U., Ghatage, P., Mahner, S., Redondo, A., Lesoin, A., Colombo, N., Vergote, I., Rosengarten, O., Ledermann, J., Pineda, M., Ellard, S., Sehouli, J., Gonzalez-Martin, A., Berton-Rigaud, D., Madry, R., Reinthaller, A., Hazard, S., Guo, W., Mirza, M.R.
Published in Annals of oncology (01.08.2018)

Get full text

Journal Article

Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva

Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva

by Horowitz, N.S, Olawaiye, A.B, Borger, D.R, Growdon, W.B, Krasner, C.N, Matulonis, U.A, Liu, J.F, Lee, J, Brard, L, Dizon, D.S
Published in Gynecologic oncology (01.10.2012)

Get full text

Journal Article

NRG/GOG 186K: A randomized phase II study of NCI-supplied cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer—Final results

NRG/GOG 186K: A randomized phase II study of NCI-supplied cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer—Final results

by Matulonis, U.A, Sill, M, Thaker, P.H, Carlson, J.W, Darus, C.J, Mannel, R.S, Bender, D.P, Higgins, R.V, Aghajanian, C
Published in Gynecologic oncology (01.06.2016)

Get full text

Journal Article

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples in a phase I study of mirvetuximab soravtansine, a FRα-targeting antibody-drug conjugate (ADC), in relapsed epithelial ovarian cancer patients

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples in a phase I study of mirvetuximab soravtansine, a FRα-targeting antibody-drug conjugate (ADC), in relapsed epithelial ovarian cancer patients

by Martin, L.P, Konner, J, Moore, K.N, Seward, S.M, Matulonis, U.A, Perez, R.P, Zhou, Y, Ponte, J, Zhao, J, Ruiz-Soto, R, Birrer, M.J
Published in Gynecologic oncology (01.06.2017)

Get full text

Journal Article

Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models

Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models

by O'Connor, M.J, Odedra, R, Palakurthi, S, Hughes, A, Lai, Z, Kirschmeier, P, Zeng, Q, Zhou, S, Dharma, S, Ivanova, E, Wang, A, Pierce, A.J, Yates, J, Powell, S, Dougherty, B, Barrett, J.C, English, J, Jewsbury, P, Matulonis, U.A, Liu, J.F
Published in European journal of cancer (1990) (01.12.2016)

Get full text

Journal Article

A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab (Bev) Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer: One-Year Results from RTOG 0921

A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab (Bev) Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer: One-Year Results from RTOG 0921

by Viswanathan, A.N, Moughan, J, Miller, B.E, Xiao, Y, Matulonis, U.A, Horowitz, N.S, Mannel, R.S, Souhami, L, Erickson, B, Gaffney, D.K
Published in International journal of radiation oncology, biology, physics (01.10.2013)

Get full text

Journal Article

PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?

PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?

by Matulonis, U.A., Monk, B.J.
Published in Annals of oncology (01.03.2017)

Get full text

Journal Article

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

by Matulonis, U.A., Shapira-Frommer, R., Santin, A.D., Lisyanskaya, A.S., Pignata, S., Vergote, I., Raspagliesi, F., Sonke, G.S., Birrer, M., Provencher, D.M., Sehouli, J., Colombo, N., González-Martín, A., Oaknin, A., Ottevanger, P.B., Rudaitis, V., Katchar, K., Wu, H., Keefe, S., Ruman, J., Ledermann, J.A.
Published in Annals of oncology (01.07.2019)

Get full text

Journal Article

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

by Matulonis, U.A., Wulf, G.M., Barry, W.T., Birrer, M., Westin, S.N., Farooq, S., Bell-McGuinn, K.M., Obermayer, E., Whalen, C., Spagnoletti, T., Luo, W., Liu, H., Hok, R.C., Aghajanian, C., Solit, D.B., Mills, G.B., Taylor, B.S., Won, H., Berger, M.F., Palakurthi, S., Liu, J., Cantley, L.C., Winer, E.
Published in Annals of oncology (01.03.2017)

Get full text

Journal Article

536P Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: Phase II subgroup analysis mirroring the patient population of an upcoming phase III study

536P Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: Phase II subgroup analysis mirroring the patient population of an upcoming phase III study

by Colombo, N., Van Gorp, T., Matulonis, U.A., Oaknin, A., Grisham, R.N., Fleming, G., Olawaiye, A., Tudor, I.C., Pashova, H.I., Lorusso, D.
Published in Annals of oncology (01.09.2022)

Get full text

Journal Article

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

by Matulonis, U.A., Penson, R.T., Domchek, S.M., Kaufman, B., Shapira-Frommer, R., Audeh, M.W., Kaye, S., Molife, L.R., Gelmon, K.A., Robertson, J.D., Mann, H., Ho, T.W., Coleman, R.L.
Published in Annals of oncology (01.06.2016)

Get full text

Journal Article

LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)

LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)

by Liu, J.F., Brady, M., Matulonis, U.A., Miller, A., Kohn, E.C., Swisher, E., Tew, W., Cloven, N., Muller, C., Bender, D., Moore, R., Michelin, D., Waggoner, S., Geller, M., Fujiwara, K., D'Andre, S., Carney, M., Secord, A.A., Walker, J., Bookman, M.A.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors

664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors

by Corcoran, R.B., Do, K.T., Cleary, J., Parikh, A., Yeku, O., Weekes, C.D., Ahronian, L., Mauri, G., Tian, J., Brugge, J., Juric, D., Flaherty, K.T., Sullivan, R.J., Clark, J., Heist, R., Matulonis, U.A., Liu, J.F., Shapiro, G.I.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors

KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors

by Cadzow, L., Gokhale, P.C., Ganapathy, S., Sullivan, P., Nayak, S., Shenker, S., Schlabach, M., Tobin, E., Matulonis, U.A., Liu, J.F., Stegmeier, F., Wylie, A.
Published in European journal of cancer (1990) (01.10.2022)

Get full text

Journal Article

592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

by Matulonis, U.A., Moore, K.N., Lorusso, D., Oaknin, A., Pignata, S., Denys, H., Colombo, N., Van Gorp, T., Konner, J., Romeo Marin, M., Harter, P., Murphy, C., Tu, Y., Zhu, F., Esteves, B., Method, M., Birrer, M.J., Coleman, R.L., O'Malley, D.
Published in Annals of oncology (01.09.2022)

Get full text

Journal Article

605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

by Moore, K.N., Lorusso, D., Oaknin, A., Pignata, S., Denys, H., Colombo, N., Van Gorp, T., Konner, J., Romeo Marin, M., Harter, P., Murphy, C., Tu, Y., Zhu, F., Esteves, B., Method, M., Birrer, M.J., Coleman, R.L., Matulonis, U.A., O'Malley, D.
Published in Annals of oncology (01.09.2022)

Get full text

Journal Article

833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer

833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer

by O'Malley, D.M., Richardson, D.L., Vergote, I.B., Gilbert, L., Castro, C., Provencher, D., Matulonis, U.A., Mantia-Smaldone, G., Martin, L., Zweidler-Mckay, P.A., Moore, K.N.
Published in Annals of oncology (01.09.2020)

Get full text

Journal Article

Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial

Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial

by Lord, R., Mirza, M.R., Woelber, L., Lesoin, A., Pineda, M.J., Peen, U., Hazard, S.J., Matulonis, U.A.
Published in Gynecologic oncology (01.06.2018)

Get full text

Journal Article

A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma

A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma

by Liu, J.F., Tayob, N., Campos, S.M., Wright, A.A., Krasner, C., Schumer, S., Horowitz, N.S., Veneris, J.L.T., Xiong, N., West, G., Quinn, R., Matulonis, U.A., Konstantinopoulos, P.A.
Published in Gynecologic oncology (01.10.2020)

Get full text

Journal Article